Pilot Study to Evaluate Escitalopram in Obsessive-compulsive Disorder

• Status: Completed
• Trial end date: 2009-03-01
• Target enrollment: 0
• Participant gender: All

Summary

This study will determine the safety and effectiveness of escitalopram (Lexapro)in treating obsessive-compulsive disorder (OCD) symptoms.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Duke University
• Collaborator: Forest Laboratories
• Treatments: Citalopram; Dexetimide

Criteria

Inclusion Criteria:

• Diagnosis of OCD

• A minimum score of 16 on the Yale Brown Obsessive-Compulsive Scale (YBOCS) at both the screening and baseline visits

Exclusion Criteria:

• Lifetime history of psychosis or cognitive dysfunction due to a general medical condition or substance use

• A primary diagnosis of another Axis I psychiatric disorder

• Alcohol or other substance abuse or dependence within the last 6 months

• Unstable medical condition

• Clinically significant laboratory abnormality

• Failure of a previous 10-week trial of citalopram of at least 40 mg/day or escitalopram 20 mg/day

• Active suicidality

• History of violent behavior in the past year or current risk of serious violence

• A history of sensitivity to citalopram or escitalopram

• Use of other investigational drugs within 30 days of baseline or other psychotropic drugs or herbs within 14 days of baseline (28 days for fluoxetine)

• Need for concurrent psychotherapeutic intervention

• Pregnant or lactating females.